Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Tufts Medical Center Inc. manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 4 distinct art units. This 1:1:1 ratio of actions to examiners and art units indicates a highly diversified portfolio where each pending matter is being evaluated in a unique technical and administrative environment. The busiest examiner, FISCHER, JOSEPH, is responsible for 1 busiest examiner pending office action.
This means the 4 pending office actions are spread evenly, with each of the 4 distinct examiners handling one case. For a practitioner, this level of distribution across 4 distinct art units means that the prosecution strategy must be highly adaptable. There is no central art unit or examiner that dominates the portfolio. Instead, each of the 4 pending office actions must be managed according to the specific standards and styles of 4 distinct examiners and their respective art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| WEHRHEIM, LINDSEY GAIL | 1 | 78.8% | +19.7% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | MIANO, JOSEPH PAUL | 134d overdue |
| 17831012 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF BABESIOSIS | JACKSON-TONGUE, LAKIA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | MIANO, JOSEPH PAUL | 134d overdue |
| 18554511 | TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF | FISCHER, JOSEPH | — |
| 18273121 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | WEHRHEIM, LINDSEY GAIL | — |
| 17831012 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF BABESIOSIS | JACKSON-TONGUE, LAKIA J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 3799 | 1 |
| 1645 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554511 | TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF | FISCHER, JOSEPH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18273121 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | WEHRHEIM, LINDSEY GAIL | 3799 | §102 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 17831012 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF BABESIOSIS | JACKSON-TONGUE, LAKIA J | 1645 | §102§112Other | Non-Final OA | — | Pending | Jun 02, 2022 |
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | MIANO, JOSEPH PAUL | 1631 | §102§103§112 | Final Rejection | 134d overdue | Pending | Jan 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial